NCT04113122招募中不适用
Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 192
- 试验地点
- 2
- 主要终点
- Cellular senescence
研究概览
简要总结
Cisplatin-combination chemotherapy causes inevitably DNA damage by platinum-DNA adduct formation of both tumor cells but also healthy cells. It therefore stands to reason that testicular cancer treatment causes an increased burden of senescent cells, which causes upregulation of the SASP resulting in a pro-inflammatory phenotype. The investigators hypothesize that this may be an important mechanism behind development of late effects and an early ageing phenotype after treatment for testicular cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •In order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria:
- •Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher)
- •Received first-line cisplatin-based chemotherapy
- •Was younger than 50 years of age at start of chemotherapy
- •In order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria:
- •Chemotherapy-group:
- •Diagnosis of metastatic testicular cancer (stage II or higher)
- •Is about to start with first-line cisplatin-based chemotherapy
- •Younger than 50 years of age at diagnosis of metastatic testicular cancer
- •Stage I control-group:
- •Diagnosis of testicular cancer stage I disease
- •Younger than 50 years of age at diagnosis of testicular cancer
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •Not able to provide informed consent (in example in case of mental or psychiatric disability)
结局指标
主要结局
Cellular senescence
时间窗: 1 year
The change in the amount of senescent cells in skin and fat tissue (defined as % of cells in which nucleus is stained positive for P16, P21 and yH2Ax)
次要结局
- Senescence-associated secretory phenotype (SASP)(1 year)
- Pulse-wave velocity(1 year)
- Adipocytokines 2(1 year)
- Platinum levels(1 year)
- Adipocytokines 1(1 year)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPCNasopharyngeal CarcinomaNCT01854203Sun Yat-sen University300
终止
2 期
Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast CancerBreast NeoplasmsNCT01167192Washington University School of Medicine10
已完成
1 期
Statins Effect on Incidence of Side Effects of Platinum Based ChemotherapySolid TumorsOtotoxicityNCT06553157Minia University56
已完成
2 期
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck CancerHead and Neck CancerNCT00423930Memorial Sloan Kettering Cancer Center44
终止
2 期
Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast CancerBreast CancerNCT00603408Washington University School of Medicine5